Influenza Vaccination in Older Patients: Immunogenicity, Epidemiology and Available Agents

Drugs & Aging

Volumn 6, Issue 5, 1995, Pages 368-387

  Glathe, Horst ^a,b   Lange, Werner ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

^b NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE;

AGED; AGING; ANTIBODY PRODUCTION; ARTICLE; GENETICS; HEALTH CARE POLICY; HUMAN; IMMUNOLOGY; INFLUENZA; ORTHOMYXOVIRUS; RISK FACTOR;

AGED; AGING; ANTIBODY FORMATION; HEALTH POLICY; HUMAN; INFLUENZA; INFLUENZA VACCINE; ORTHOMYXOVIRIDAE; RISK FACTORS; VACCINES, INACTIVATED;

EID: 0029294527     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/00002512-199506050-00004     Document Type: Article

References (180)

1. A virus obtained from influenza patients
2. A new type of virus from epidemic influenza
3. Influenza B infections in the community and the family: the epidemics of 1976–1977 and 1979–1980 in Houston, Texas
4. Identification of another epidemic respiratory disease
5. New aspects of influenza viruses
6. The natural history of influenza A viruses
7. The immune response to influenza infection
8. Molecular mechanism of variation in influenza viruses
9. Evolution of influenza A and B viruses: conservation of structural features in the hemagglutinin genes
10. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase
11. Immunology of influenza
12. Induction of partial immunity by a neuraminidase-specific vaccine
13. Antiviral immunity induced by recombinant nucleoprotein of influenza A virus I: characteristics and cross-reactivity of T cell responses
14. Molecular basis of the specific anti-influenza action of amantadine
15. The in vivo production of ‘new’ influenza viruses
16. The nucleoprotein as a possible major factor in determining host specificity of influenza H3N2 virus
17. The prevalence of influenza viruses in swine and the antigenic and genetic relatedness of influenza viruses from man and swine
18. Recycling of Asian and Hong Kong influenza A virus hemagglutinins in man
19. Evidence for host-cell selection of influenza virus antigenic variants
20. Structural changes in the haemagglutinin which accompany egg adaptation of an A (H1N1) virus
21. Host cell mediated variation in H3N2 influenza viruses
22. Determinants of immunity to influenza in man
23. Natural or vaccine-induced immunity as a predictor of immunity in the face of natural challenge with influenza virus
24. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses
25. Statistical inference for infections diseases — risk specific household and community transmission parameters
26. Serological responses in volunteers to inactivated trivalent subunit influenza vaccine: antibody reactivity with epidemic influenza A and B strains and evidence of a rapid immune response
27. Early kinetics of antibody response to inactivated influenza vaccine
28. A comparison of live and inactivated influenza A (H1N1) virus vaccines 2: long-term immunity
29. A serological recapitulation of human infection with different strains of influenza viruses
30. Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus
31. Original antigenic sin in ferrets: the responses to sequential infections with influenza viruses
32. Strain specifity of serum antibody to the haemagglutinin of influenza A (H3N2) viruses in children following immunization or natural infection
33. The specificity of the anti-haemagglutinin antibody response induced in man by immunization and by natural infection
34. Development and persistence of systemic antibody responses in adults given live attenuated and inactivated influenza A virus vaccine
35. Immune response in serum and respiratory tract secretions following vaccination with a live cold-recombinant (CR 35) and inactivated A/USSR/77 influenza virus vaccine
36. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus
37. Cytotoxic T cells to influenza
38. The human cytotoxic T cell response to influenza A vaccination
39. Antibody and cytotoxic T lymphocyte responses of humans to live and inactivated influenza vaccines
40. Induction of influenza A cross-reactive cytotoxic T cells by a nucleoprotein/haemagglutinin preparation
41. HA2 subunit of influenza H1 and H2 subtype viruses induce a protective cross-reactive cytotoxic T lymphocyte response
42. The cellular and subcellular basis of immunosenescence
43. In vivo T cell activation, in vitro defective IL-2 secretion, and response to influenza in elderly women
44. Hepatitis B vaccination in the elderly
45. Serum IgG subclass responses of humans to inactivated and live influenza A vaccine compared to natural infection with influenza A
46. Effect of age on immunoglobulin G subclass antibody responses to inactivated influenza vaccine
47. Improvement of the immunoglobulin subclass response to influenza vaccine in elderly nursing home residents by the use of high-dose vaccines
48. Aspects of the molecular structure of IgG subclasses
49. Altered regulation of IL-6 production with normal aging: possible linkage to the age-associated decline in dihydroepiandrosterone and its sulfated derivative
50. Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine
51. Enhancement of anti-influenza A virus cytotoxicity following influenza A vaccination in older, chronically ill patients
52. Virus survival as a seasonal factor in influenza and poliomyelitis
53. Influenza surveillance
54. Estimating household and community transmission parameters for influenza
55. The Tecumseh study of respiratory illness, IX: occurrence of influenza in the community, 1966–1971
56. Serious morbidity and mortality associated with influenza epidemics
57. Mortality from influenza and pneumonia in 50 large cities of the United States, 1910–1929
58. Influenza surveillance in the former German Democratic Republic in the period 1969–1990 [in German]
59. Association of excess mortality from chronic nonspecific lung disease with epidemics of influenza
60. Assessing trends in mortality in 121 U.S. cities, 1970-1979, from all causes and from pneumonia and from influenza
61. An evaluation of influenza mortality surveillance, 1962–1979, II: percentage of pneumonia and influenza deaths as an indicator of influenza activity
62. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985
63. Mortality from influenza and allied infections in South Australia during 1968–1981
64. The effect of influenza epidemics on the hospitalization of persons 65 years and older
65. Impact of influenza on mortality in relation to age and underlying disease, 1967–1989
66. Impact of influenza in a defined adult population
67. Hidden influenza deaths
68. Influenza virus infections of the chick embryo by the amniotic route, I: general character of the infections
69. A simplified procedure for the concentration and purification of influenza virus
70. Purified influenza virus vaccine: a study of viral reactivity and antigenicity
71. Purification of large quantities of influenza virus by density gradient centrifugation
72. Correlated studies of a recombinant influenza-virus vaccine, I: derivation of vaccine and characterization of virus and vaccine
73. 4
74. Selective solubilization of haemagglutinin and neuraminidase from influenza viruses
75. A surface antigen influenza vaccine
76. Endotoxin content and clinical reactivity to influenza vaccines
77. A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole virus and split-product influenza vaccines in children
78. Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine
79. Preparation and immunogenicity of an influenza virus hemagglutinin and neuraminidase subunit vaccine
80. Morphological and biochemical characterization of influenza vaccines available in the United Kingdom
81. Studies on the pathogenesis of fever with influenza virus
82. Recommended composition of influenza virus vaccines for use in the 1994–1995 season
83. Development of cold-adapted-recombinant live, attenuated influenza A vaccines in the USA and USSR
84. Prospects for influenza type B live attenuated vaccines
85. Analysis of genome composition and reactogenicity of recombinants of cold-adapted and virulent virus strains
86. Influenza A reassortant virus derived from avian and human influenza A viruses is attenuated and immunogenic in monkeys
87. Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes
88. Influenza in the elderly: report of an outbreak and a review of vaccine effectiveness reports
89. Effects of vaccination on an influenza epidemic in a geriatric hotel
90. Efficacy of the antiinfluenza A vaccination during epidemics due to A/Vic/3/75 and A/Texas/1/77 viruses
91. Efficacy of influenza vaccine in nursing homes: reduction in illness and complications during an influenza A (H3N2) epidemic
92. Viral respiratory disease at Lowry Air Force Base in Denver, 1952–82
93. Association of influenza immunization with reduction in mortality in an elderly population
94. Influenza vaccine and pneumonia mortality in a nursing home population
95. Role of influenza vaccination in the elderly during an epidemic of A/H1N1 virus in 1988–1989: clinical and serological data
96. Effect of nursing home size and influenza vaccination rates on the risk of institutional outbreaks during an influenza A (H3N2) epidemic
97. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly
98. Who needs influenza vaccine
99. Influenza vaccination of elderly persons: reduction in pneumonia and influenza hospitalizations and deaths
100. Effectiveness of inactivated influenza vaccine among non-institutionalized elderly persons
101. Assessment of genetic relatedness among haemagglutinins of type A influenza viruses by competition radioimmunoassay
102. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community
103. Influenza vaccines for the elderly
104. Clinical effectiveness of influenza vaccination in Manitoba
105. The efficacy of influenza vaccination in elderly individuals: a randomised doubleblind placebo-controlled-trial
106. Case control study in Ohio and Pennsylvania on prevention of hospitalization by influenza vaccination
107. Influenza: its control in persons and populations
108. Antibody induction by influenza vaccines in the elderly: a review of the literature
109. Zum Problem der altersabhängigen Immunantwort nach Influenzaschutzimpfung
110. Relation of chronic disease and immune response to influenza vaccine in the elderly
111. Influenza and pneumococcal immunization of patients with neoplastic diseases
112. Efficacy of sequential annual vaccination with inactivated influenza virus vaccine
113. Responses of elderly subjects to a new subunit influenza vaccine
114. Antibody response to whole-virus and split-virus influenza vaccines in successful ageing
115. Split-virus influenza vaccines: do they provide adequate immunity in the elderly
116. Increased immunogenicity of inactivated influenza vaccine containing purified surface-antigen compared with whole virus in elderly women
117. Vaccine-induced antibodies to heterologous influenza A H1N1 viruses: effects of aging and ‘original antigenic sin’
118. Immunization of elderly people with high doses of influenza vaccine
119. Antibody response to inactivated influenza vaccines of various antigenic concentrations
120. Application of an improved single-radial-immunodiffusion technique for the assay of haemagglutinin antigen content of whole virus and subunit influenza vaccines
121. Safety and immunogenicity of 45 μg supplemental dose of inactivated split-virus influenza B vaccine in the elderly
122. A graded-dose study of inactivated surface antigen influenza B vaccine in volunteers: reactogenicity, antibody response and protection to challenge virus infection
123. Influenza vaccines: the effect of vaccine dose on antibody response in primed populations during the ongoing interopandemic period — review of the literature
124. Antibody response after influenza immunization with various vaccine doses: a double blind, placebo-controlled, multi-centre, doseresponse study in elderly nursing-home residents and young volunteers
125. Comparison of humoral immune responses to trivalent influenza split vaccine in young, middle aged, and elderly people
126. Comparison of one- and two-dose regimes of influenza vaccine for elderly men
127. Immunization of elderly people with two doses of influenza vaccine
128. Enhancement of the protective efficacy of inactivated influenza A virus vaccine in aged mice by IL-2 liposomes
129. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit
130. Development of a new type of influenza subunit vaccine made by muramyl-dipeptide-liposome: enhancement of humoral and cellular immune response
131. The ISCOM antigen-presenting system
132. New approaches to vaccine delivery
133. Immunogenicity of new virosome influenza vaccine in elderly people
134. Evaluation of inactivated influenza vaccine with or without supplemental live attenuated cold-adapted vaccine in high-risk elderly
135. Protective efficacy of combined live intranasal and inactivated Influenza A virus vaccines in the elderly
136. Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines
137. Use of live vaccine in the elderly
138. A randomized trial of cold-adapted and inactivated vaccines in the prevention of influenza A disease
139. In elderly persons live attenuated influenza A vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory
140. Failure of inactivated influenza vaccine to protect an aged population
141. Failure of influenza vaccination in the aged
142. Immunogenicity and reactogenicity of a trivalent influenza virus split vaccine [in German]
143. Immune response to influenza vaccination of elderly people: a randomised double-blind placebo-controlled trial
144. Influenza subunit vaccine — ten years experience
145. Evaluation of adverse effects after influenza vaccination in hospital personnel
146. Immunogenicity and adverse reactions of influenza vaccination in elderly patients given acetaminophen or placebo
147. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial
148. Frequency of adverse reactions to influenza vaccine in the elderly
149. Influenza immunization: the U.S. experience
150. Reasons for non-immunization against influenza in the aged
151. Influenza vaccination in asthma
152. Safe administration of influenza vaccine in asthmatic children sensitive to egg proteins
153. Decreased elimination of theophylline after influenza vaccination
154. Depression of aminopyrine metabolism by influenza vaccination
155. Increased serum phenytoin concentration following influenza vaccination
156. Influenza vaccination and warfarin or theophylline toxicity in nursing-home residents
157. The effect of split virus influenza vaccination on theophylline pharmacokinetics
158. Über neurologische Komplikationen nach der Influenzaschutzimpfung
159. Guillan-Barre syndrome and influenza vaccination in the US army, 1980–1988
160. Reassessment of the association between Guillan-Barre’ syndrome and receipt of swine influenza vaccine in 1976–1977 results of a two state study
161. Amantadine use for control of institutional influenza A
162. Prevention, management, and control of influenza: role of amantadine
163. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection
164. Control of influenza A outbreaks in nursing homes: amantadine as a adjunct to vaccine: 1989–1990
165. Emergence and possible transmission of amantadine resistant viruses during nursing home outbreaks of influenza A (H3N2)
166. Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function
167. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance
168. Overview of national approaches to influenza vaccination
169. Clinical practice and public policy for influenza and pneumococcal vaccination of the elderly
170. Immunization policies and vaccine coverage among adults: the risk for missed opportunities
171. Organizational strategies to improve influenza vaccine delivery: a standing order in a general medical clinic
172. Barriers to influenza vaccine acceptance. A survey of physicians and nurses
173. Achieving the national health objective for influenza immunization: success of an institution-wide vaccination programm
174. Rational design of sialidase-based inhibitors of influenza virus replication